Valneva says results of its COVID vaccine study positive

Monday, 18. October 2021 08:07

Valneva SE said on Monday that the results of its Phase 3 COVID-19 vaccine study yielded positive results, with the shot producing "superior neutralizing antibody titer levels" similar to those contained in AstraZeneca's vaccine.

The French vaccine maker noted that its inactivated, adjuvanted COVID-19 vaccine candidate VLA2001 was well tolerated among more than 4,000 trialed adult participants, with the "neutralizing antibody seroconversion rate above 95%."

Commenting on the breakthrough, CEO Thomas Lingelbach said that the company is "committed to bringing its differentiated vaccine candidate to licensure as quickly as possible and continue to believe that it will be able to make an important contribution to the global fight against the COVID-19 pandemic."

Related Links: Valneva SE
Breaking the News / ND